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EXPLORING THE BENEFITS OF PRENATAL ASPIRIN IN PATIENTS AT RISK 





Background: Preeclampsia is one of the leading causes of maternal and 
perinatal morbidity and mortality, affecting 2-8% of pregnancies worldwide.  It is 
estimated that 76,000 women and 500,000 babies die from this disease each 
year globally.  Preeclampsia is characterized as hypertension associated with the 
onset of proteinuria, maternal organ dysfunction or uteroplacental dysfunction 
occurring at or after 20 weeks of gestation.  In addition to its effects on 
pregnancy, preeclampsia may also have long-term adverse effects on women 
who experience the disorder and their children later on in life. Currently, the only 
cure for preeclampsia is delivery, which is often associated with preterm birth, 
increasing the risk of neonatal death.  Daily low-dose aspirin (81mg) has been 
shown to have a preventive effect on preeclampsia in women at high risk of 
developing the disorder. 
Objective: To analyze patient data collected at Boston Medical Center to 




Methods: There were 2648 obstetric deliveries at Boston Medical Center in the 
two-year span of 2017-2018. Using R, statistical analyses were performed to 
determine the difference in birth outcomes between the prenatal aspirin 
prescribed group and the non-aspirin prescribed group as well as the effect of 
prenatal aspirin on pregnancy outcomes. Logarithmic and linear models as well 
as basic statistical methods were employed for the analyses. 
Results: The prenatal aspirin prescribed population had higher major and 
moderate risk factors as well as worse birth outcomes, Apgar scores and 
birthweight as compared with the non-prescribed population.  However, prenatal 
aspirin may reduce the adverse effects of both major and moderate risk factors 
on birth outcomes. 
Conclusions: Prenatal aspirin may have beneficial effects on birth outcomes, 
and the pregnant population at Boston Medical Center may benefit from taking 
low-dose aspirin. This study was carried out retrospectively with a cohort that 
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The Health Burden of Preeclampsia 
Preeclampsia (PE) is one of the leading causes of maternal and perinatal 
morbidity and mortality, affecting 2-8% of pregnancies.  It is a multisystem 
disease defined as new-onset hypertension during pregnancy associated with 
the onset of proteinuria, maternal organ (such as liver, kidney, and brain) 
dysfunction or uteroplacental dysfunction occurring at or after 20 weeks of 
gestation (Duley et al., 2019; Eiland et al., 2012; LeFevre and Force, 2014; Poon 
et al., 2019). Although not mutually exclusive, preeclampsia can be subclassified 
into early-onset (with delivery at <34 weeks of gestation), preterm (with delivery 
at <37 weeks of gestation), late-onset (with delivery at ≥34 weeks of gestation), 
and term (with delivery at ≥37 weeks of gestation). Early-onset preeclampsia is 
associated with a much higher risk of severe adverse outcomes (Poon et al., 
2019).  
  
Complications of Preeclampsia 
There are many complications that may arise from preeclampsia. 
Hypertension may be accompanied by systemic organ problems or even organ 
failure. Some of these complications include cerebral symptoms, liver and kidney 
failure, endothelial dysfunction, altered immunological adaptation, exaggerated 
inflammatory response, and increased coagulation with abnormal thrombin 
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production. It was found that preeclampsia increased the probability of an 
adverse event from 4.6% to 10.1% in mothers and from 7.8% to 15.4% in infants 
while lowering gestational age by an average of 1.7 weeks. Furthermore, there 
are many potential complications for the infant such as respiratory distress, heart 
disease, metabolic syndrome, and death (Stevens et al., 2017). 
  
Additional Adverse Effects of Preeclampsia 
Women who have suffered preeclampsia may experience additional 
health problems later on in life and have an increased risk of death from future 
cardiovascular disease, hypertension, stroke, renal disorder, metabolic 
syndrome, and diabetes. The life expectancy of these women is decreased by an 
average of 10 years. In addition, there is significant impact on children born to 
women with preeclampsia in the long term, and these children have an increased 
risk in the future of insulin resistance, coronary artery disease, and hypertension 
(Poon et al., 2019). 
  
Pathological Cause of Preeclampsia 
Preeclampsia is diagnosed as a mixed collection of diseases and 
symptoms; thus, elucidation of the mechanism behind preeclampsia has proven 
difficult. The exact cause of preeclampsia is unclear, and many theories have 
been proposed on the etiology of the disorder. Most of these theories suggest 
that the disease is a series of sequential events triggered by multiple factors 
including a disturbance in usual maternal inflammatory response, abnormal 
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immunity, and both activation and damage of endothelial cells with aberrant 
hemodynamic milieu (Eiland et al., 2012). One of the longest standing theories is 
related to the placenta in that there is often abnormal trophoblastic invasion of 
the uterine spinal arteries in women who develop preeclampsia. This can cause 
decreased placental perfusion and possibly placental hypoxia. However, it is 
known that not all women who have abnormal cytotrophoblast invasion develop 
preeclampsia, and not all women with preeclampsia have abnormal 
cytotrophoblast invasion. This suggests that although the placenta seems to play 
a role in the pathogenesis of preeclampsia, there are other factors that may be 
involved in the development of preeclampsia (Roberts and Escudero, 
2012).  Alternative theories include possible genetic involvement, endothelial 
dysfunction, or an immune system component involving the maternal-fetal 
balance. Also proposed is a theory based on maladaptation to normal 
physiological changes that occur with pregnancy (Kanasaki and Kalluri, 2009). 
  
Treatment and Prevention of Preeclampsia 
Once developed, the progression of preeclampsia cannot be completely 
reversed or stopped. Currently, the only cure for preeclampsia is delivery, while 
other treatments aim at delaying the pathological progression or alleviating the 
severity of the disease so as to prolong pregnancy. Early onset preeclampsia 
often requires preterm delivery, and these preterm infants are at increased risk 
for morbidity, mortality, and complications (Chaemsaithong et al., 2019; Eiland et 
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al., 2012; LeFevre and Force, 2014; Poon et al., 2019). There have been many 
studies investigating the role of biochemical markers and biophysical markers in 
the prediction of preeclampsia, but screening for preeclampsia in low-risk women 
was associated with very low positive predictive value (ACOG, 2019). To date, 
there is no intervention that has been proven to completely eliminate the risk of 
preeclampsia, but there is some evidence backing possible prevention methods 
to reduce the risk. Past studies with regards to nutritional interventions, such as 
vitamin C and E supplementation and sodium restriction, showed possible 
reduction in risk but were statistically insignificant. One nutritional intervention 
that showed some promise was calcium supplementation. Specifically, it was 
determined that women with low-baseline calcium intake had a reduced risk of 
preeclampsia after being prescribed calcium supplementation (ACOG, 2019). 
Administration of low-dose aspirin is possibly one of the most promising 
interventions currently available in reducing the risk of preeclampsia and will be 
discussed below. 
 
Aspirin in the Prevention of Preeclampsia 
         Low-dose aspirin has been demonstrated to reduce the incidence of 
preeclampsia in women at high risk of the disorder without increasing significant 
adverse effects. Its prophylactic use has thus been recommended for this group 




Aspirin’s Mechanism of Action 
Aspirin, also known as acetylsalicylic acid, is one of the most widely used 
medications globally (Atallah et al., 2017; Chaemsaithong et al., 2019). A 
precursor to aspirin that is found in the leaves of white willow trees has been 
used for its effects on reducing pain and fever for thousands of years (Atallah et 
al., 2017; Chaemsaithong et al., 2019).  The purest and most stable form of 
acetylsalicylic acid was obtained in 1897 by a chemist named Felix Hoffmann at 
Bayer Company, and the company later named the product aspirin. Soon, aspirin 
was shown to have antipyretic and analgesic effects and quickly rose in 
popularity. It was not until 1971 that aspirin’s mechanism of action was 
determined. John Vane demonstrated that aspirin inhibits prostaglandin 
synthesis (Vane, 1971), and he was awarded a Nobel Prize in 1982 for this 
discovery (Harding, 2004). 
Since Vane’s discovery, the mechanism of action of aspirin has been 
further elucidated. Aspirin has been found to be an irreversible inhibitor of 
cyclooxygenase (COX), which metabolizes arachidonic acid, a 20-chain fatty 
acid, to produce prostaglandins and thromboxane A2, collectively known as 
prostanoids (Figure 1). Prostacyclin produced in endothelial cells is a vasodilator 
and also inhibits platelet aggregation and adhesion, while thromboxane A2, 
which is produced by platelets and the placenta, induces platelet aggregation, 
vasoconstricts, and induces proliferation of vascular smooth muscle cell (Botting, 
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2010; Ricciotti and FitzGerald, 2011; Smith, 1989). It is through this mechanism 
of action that aspirin offers many benefits as a medication. 
          
 
The half-life of aspirin is very short, allowing newly synthesized COX to 
resume the production of prostaglandin a few hours after a dose of aspirin. Thus, 
the endothelium recovers its physiological state with normal basal prostacyclin 
secretion (Das, 2005). Because platelets, where thromboxane A2 is synthesized, 
are anuclear and cannot compensate for aspirin inhibition through de novo 
synthesis of COX protein, the inhibition of COX lasts for the whole life span of 
each platelet. Therefore, a daily single low-dose aspirin reduces the levels of 
Figure 1. Aspirin suppresses synthesis of prostacyclin and thromboxane A2






prostaglandin F2 alpha (PGF2a)









thromboxane A2 without affecting production of prostacyclin (Atallah et al., 2017; 
Perneby et al., 2011; Sibai et al., 1989).  Low-dose aspirin has thus offered 
additional benefits besides its original indications in pain, fever, and 
inflammation. Aspirin’s perhaps most notable benefit has been in the primary 
prevention of atherosclerotic cardiovascular disease (Atallah et al., 2017; Bittner, 
2019). 
 
The Benefits of Aspirin in Preeclampsia 
The beneficial effect of low-dose (50-150 mg daily) aspirin has also been 
examined in obstetrics. In a letter to the editor in 1979, Crandon and Isherwood 
conducted a prospective study and observed an association between reduced 
incidence of preeclampsia and aspirin intake. They noted that 4% (2/48) of the 
pregnant women who had taken aspirin frequently during pregnancy developed 
preeclampsia as compared with 16% (16/98) of the women who had not taken 
aspirin (Crandon and Isherwood, 1979). Beaufils et al. provided the first evidence 
of the preventive effects of aspirin on preeclampsia in a randomized study, 
reporting that among 102 patients at high risk, the prevalence of preeclampsia 
was significantly reduced in the group taking aspirin when compared with the 
non-treatment group (0/48 vs 6/45, p<0.05) (Beaufils et al., 1985). It was later 
discovered that platelet thromboxane A2 production was markedly increased 
while prostacyclin production was significantly decreased in preeclampsia 
(Walsh, 1989), offering a rationale for the use of low-dose aspirin in the 
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prevention of preeclampsia given the effect of low-dose aspirin in the reversal of 
prostacyclin and thromboxane A2 imbalance (Perneby et al., 2011; Sibai et al., 
1989) as previously discussed. In addition, the anti-inflammatory, anti-
angiogenesis, and antiplatelet properties of low-dose aspirin are also believed to 
contribute to its preventative effects on preeclampsia (LeFevre and Force, 
2014).  These observations together have inspired a large number of trials to 
examine the effect of low-dose aspirin in the prevention of preeclampsia. The 
results from these studies have substantiated the beneficial effect of low-dose 
aspirin in reducing or delaying the incidence of preeclampsia in pregnant women 
at high risk (Andrikopoulou et al., 2018; Atallah et al., 2017; Bujold et al., 2010; 
Gu et al., 2020; LeFevre and Force, 2014; Poon et al., 2019; Roberge et al., 
2018; Rolnik et al., 2017a). 
In a recent study, Duley et al. analyzed data from 77 trials from a wide 
range of countries and performed a meta-analysis of the data from 74 of these 
trials (3 trials were not included in the meta-analysis), which included 40,016 
women and their newborn babies.  The trials included nine large trials that had 
recruited over 1000 women, and the aspirin doses used were 50 mg (1 trial with 
1106 women), 60 mg (5 trials with 22,322 women), 75 mg (1 trial with 3697 
women), 100 mg (1 trial with 3294 women), and 150 mg (1 trial with 1776 
women).  They observed various beneficial effects of low-dose aspirin in 
pregnancy. The authors concluded that administration of low-dose aspirin in 
pregnant women resulted in small-to-moderate benefits, including reductions in 
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pre-eclampsia (16 fewer per 1000 women treated), preterm births (16 fewer per 
1000 treated), small-for-gestational age births (seven fewer per 1000 treated) 
and fetal or neonatal death (five fewer per 1000 treated). Overall, administering 
aspirin to 1000 women led to 20 fewer pregnancies with serious adverse 
outcomes (Duley et al., 2019).  As reported in numerous previous studies, the 
Duley study observed no significant side effects of low-dose aspirin during 
pregnancy.  As most women were recruited after 12 weeks' gestation to the trials 
reviewed by Duley, it would be interesting to see whether initiating treatment 
before 12 weeks’ gestation would have additional benefits. In an meta-analysis 
from eight randomized controlled trials from 1985 to 2018 with aspirin 
commencing at <11 week’s gestation in a combined total of 1426 participants, 
Chaemsaithng et al. reported that low-dose (50-100 mg daily) aspirin started at 
<11 weeks’ gestation led to a modest, but insignificant, reduction in the risk of 
preeclampsia (RR 0.52; 95% CI, 0.23-1.17, p=.115), gestational hypertension 
(RR, 0.49; 95% CI, 0.20-1.21; p=.0.121), and any hypertensive disorders in 
pregnancy (RR,0.59; 95% CI, 0.33-1.04, p=.067). Notably, the analysis found 
that early initiation of low-dose aspirin was associated with a significant decrease 
in the risk of preterm delivery (RR, 0.52; 95% CI, 0.27-0.97, p=.040) 
(Chaemsaithong et al., 2019). 
 




Given the benefits of low-dose aspirin in the prevention of preeclampsia, 
many professional organizations around the world have recommended 
prophylactic use of low-dose aspirin for preeclampsia prevention. The U.S. 
Preventive Services Task Force (USPSTF) recommends the use of low-dose 
aspirin (81 mg/day) as a preventive medication for women at high risk of 
preeclampsia after 12 weeks of gestation. Their findings show that preventive 
use of low-dose aspirin (ranged from 60 to 150 mg/d) reduced the risk of 
preeclampsia by 24%, the risk for preterm birth by 14%, and intrauterine growth 
restriction by 20% without increasing the risks for placental abruption, postpartum 
hemorrhage, fetal intracranial bleeding, or perinatal mortality (LeFevre and 
Force, 2014). 
The International Federation of Gynecology and Obstetrics (FIGO) has 
recently recommended that women at high risk of preeclampsia should take 
aspirin at a dose of approximately 150 mg daily at night starting at 11-14+6 weeks 
of gestation until 36 weeks of gestation, when delivery occurs, or when 
preeclampsia is diagnosed (Poon et al., 2019). 
 
 Challenges in the Implementation of Prenatal Aspirin Intake 
Recommendations  
         In spite of the ample evidence for the preventive effects of low-dose 
aspirin in preeclampsia, the benefit of low-dose aspirin in pregnant women with 
high risk pregnancies has not been universally appreciated by patients as well as 
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clinicians.  The barriers to a broader implementation of the recommended low-
dose aspirin for high-risk pregnancies comes from several fronts.  
 
Reconciliation of Conflicting Prenatal Aspirin Observations 
One challenge is to reconcile the conflicting observations in prenatal 
aspirin (PNA) research regarding the extent of preventive benefits, effective 
doses, and timing of administration. While numerous studies have demonstrated 
significant preventive effects of low-dose aspirin on preeclampsia in high-risk 
women as discussed previously, some studies have observed no such significant 
benefit when treatment was started before 11 weeks’ gestation (Chaemsaithong 
et al., 2019), suggesting that there may be confounding factors that influence the 
outcome of the medication.  This discrepancy may be due to a number of 
reasons including the selection criteria for “high-risk” women, aspirin dose 
chosen, and the gestational age at which aspirin is started in these studies. 
Indeed, different studies have employed distinct methods or algorithms to select 
“high-risk” participants for their trials or meta-analyses (Chaemsaithong et al., 
2019; Gu et al., 2020; Roberge et al., 2018; Rolnik et al., 2017a; Rolnik et al., 
2017b).  Some studies report a dose-dependent effect of aspirin in pregnant 
women (Bujold et al., 2010; Caron et al., 2009) with a beneficial effect on preterm 
preeclampsia, but not term preeclampsia, that is observed only at a daily dose of 
≥ 100 mg and when the medication is started at 16 weeks of gestation (Roberge 
et al., 2018; Roberge et al., 2017). In contrast, other studies found that the 
benefit of aspirin in reducing preeclampsia was not influenced by the dose of 
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aspirin or whether treatment was initiated before or after 16 weeks of gestation 
(Askie et al., 2007; Meher et al., 2017). 
Therefore, to fully take advantage of the beneficial effects of aspirin in the 
prevention of preeclampsia, it is important to determine the criteria that would 
allow accurate prediction of preeclampsia early on in pregnancy and thus select 
high-risk women for effective treatment. In addition, more studies are needed to 
determine the optimal dose of aspirin for prevention given the current confusion 
about the effective dose in the literature as discussed.  This is particularly 
important as it appears that higher doses (up to150 mg daily) of aspirin have 
resulted in better outcomes (Askie et al., 2007; Rolnik et al., 2017a), but the 
potential side effects of higher doses of aspirin in pregnant women and in fetuses 
need to be taken into consideration, especially given that the long-term effect of 
aspirin at higher concentrations on women who receive such treatment and their 
children have not yet been fully determined. 
  
Raising Awareness of the Preventive Benefits of Low-dose Aspirin in 
Preeclampsia 
Another challenge in the implementation of prenatal aspirin is that there 
needs to be increased awareness among the public about the preventive benefits 
of low-dose aspirin. The common perception among pregnant women that aspirin 
has more risks than benefits represents a barrier in the implementation of 
prenatal aspirin as an intervention to prevent preeclampsia (Damase-Michel et 
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al., 2009). Thus, there is a need to provide informed education about the 
preventive benefits of low-dose aspirin in pregnant women at high risk of 
preeclampsia. 
  
Encouraging Patients’ Adherence to Medication 
An additional challenge is to promote patients’ adherence to medication. 
Adherence to medication is defined as when a patient takes prescribed agents at 
doses and times recommended by a healthcare provider and agreed to by the 
patient. Patient adherence is crucial as patient nonadherence to prescribed 
medications is associated with poor therapeutic outcomes, worsening 
progression of diseases, and billions per year in avoidable healthcare costs (Iuga 
and McGuire, 2014). 
Many factors can influence a patient’s adherence. It was found that a 
longer duration of treatment influences a patient’s beliefs about medication 
effectiveness. In addition, patients suffering from chronic diseases, in particular 
those with fluctuation or absence of symptoms, such as hypertension, are more 
likely to be non-compliant (Jin et al., 2008). More specific to pregnant women, 
recent risk perception studies have shown that pregnant women tend to 
overestimate the magnitude of teratogenic risks of medications leading to poor 
adherence and/or discontinuation of treatment, and pregnant women are most 
concerned about having a child with a birth defect, a miscarriage, or their child 
developing an allergic disease (Mulder et al., 2018). 
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The Prenatal Aspirin Project at Boston Medical Center  
The Prenatal Aspirin Project is an initiative at Boston Medical Center 
(BMC) to increase the implementation of the recommendations of the U.S. 
Preventive Services Task Force on use of low-dose aspirin among pregnant 
women with high risk of developing preeclampsia. Dr. Jodi Abbott at BMC is the 
director of the project. I joined Dr. Abbott’s group in September 2019 to 








1. Analyze patient population data collected by the Prenatal Aspirin Project 
at Boston Medical Center 
2. Model the effects of prenatal aspirin prescribed to pregnant patients at 
Boston Medical Center  
3. Explore whether the benefits of prenatal aspirin are demonstrated in the 








Patient Data Collection 
The Prenatal Aspirin Project is an initiative at BMC to increase the 
implementation of the recommendations of the U.S. Preventive Services Task 
Force on use of low-dose aspirin among pregnant women with high risk of 
developing preeclampsia. In this retrospective study, data from 2648 obstetric 
deliveries at BMC in 2017 and 2018 were collected.    
Among the data collected were demographics as well as information on 
the patient’s intake/first obstetrics appointment, parity, health indicator history, 
risk factors, prenatal aspirin (PNA) prescription, post-delivery, aspirin use, 
neonates, and outcomes. The full list of information collected can be found in 
Table 1. Major risk factors were considered to be history of preeclampsia, history 
of multifetal gestation, chronic hypertension, history of gestational hypertension, 
diabetes mellitus, and autoimmune disease. Moderate risk factors included 
nulliparity, body mass index over 30, family history of preeclampsia in mother 
and sister, age over 35 at initial intake appointment, patient self-identified 
race/ethnicity as black, social insurance (Medicaid or safety net), history of 
intrauterine growth restriction, history of adverse pregnancy outcomes, and last 
pregnancy over 10 years. Those who had one major risk factor or at least two 
moderate risk factors were determined to be eligible for prenatal aspirin. 
Outcome measures included term/preterm birth, Apgar score at 1 minute, Apgar 
score at 5 minutes, and birthweight. 
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Table 1. Patient Variables Collected 
   
Prenatal site of care 
Date intake/first obstetrics appointment 
Provider at intake 
Type of provider associated with intake 
visit 
Name of provider at intake 
Gestational age at intake 




Country of origin 
Body mass index at intake 
Parity 
Smoking history 
Substance abuse history 
Mental health history 
History of preeclampsia 
History of multifetal gestation 
Chronic hypertension 





Family history of preeclampsia in 
mother or sister 
Social insurance 
Name of insurance 
History of IUGR 
History of adverse outcomes 
Specified adverse outcome 
Last pregnancy >10 years 
PNA screening at intake 
PNA prescribed at intake 
Medically non-eligible reason for PNA 
Aspirin before pregnancy 
Gestational age at which PNA was 
started / prescribed 
Time on aspirin 
Type of provider who prescribed PNA 
Maternal Fetal Medicine prescribed 
PNA provider name 
Complications associated with PNA 
Delivery date 
Maternal age at delivery 
Gestational age at delivery 
Birth type (vaginal spontaneous delivery 
or cesarean section) 
Multifetal at delivery 
Qualitative blood loss at delivery 
Transfusion requirement at delivery 
Units transfused 
Preeclampsia or HELLP syndrome at 
delivery 
Gestational hypertension at delivery 
Intrauterine growth restriction at 
delivery 
Pregnancy outcome (term vs preterm)  
Preterm induction 
Reason for induction 
Preterm spontaneous delivery 
Labor induced 
Reason for induction 
Method of induction 
Reason for cesarean section 
Other delivery complications 
Status of baby 
Patient qualified for aspirin 
Apgar score at 1 & 5 minute(s) 
Birth weight 
Sex of baby 
Type of anesthesia, if any, for delivery 
Postpartum severe range blood pressure 
(>160/>110) 
Need for antihypertensives 
Need for antihypertensives at discharge 
Visiting nurse association services at 
discharge 
Need for magnesium sulfate 
Vaginal delivery, length of stay 
Cesarean section, length of stay 
Return to obstetrics triage and reason 
Emergency Department visits 
Reason for readmission 
Intensive Care Unit stay 









Outcome differences between patients who were prescribed aspirin 
(herein referred to as the prescribed group) and patients who were not (referred 
to as the non-prescribed group) were statistically analyzed with R and R 
packages ggplot2, devtools, ggeffects, and RColorBrewer. We analyzed different 
models to determine the effects of different factors relating to preeclampsia and 
pregnancy outcomes.  
We aimed to first see any differences in three different pregnancy 
outcome measures (Apgar score at one minute, Apgar score at five minutes, and 
birthweight) between the prescribed group and the non-prescribed group. We 
compared the means of the three measures using a two sample Welch T test. 
We also compared the proportion of preterm births for both the prescribed and 
the non-prescribed groups by using a two-sample proportion test and conducted 
a chi square test to see if there was any association between term/preterm and 
prescribed/non-prescribed. While we know pregnancy outcome measures may 
be affected by many different factors, we were interested in getting a general 
picture.  
We used two different modeling strategies, logistic regression and linear 
regression, in order to create different regression equations for the two groups. 
We then analyzed and compared the respective regression equations to see if 
there was any difference between the two groups. We first used a binary logistic 
model to estimate the probability of a term vs preterm birth for both groups. We 
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then converted the coefficients of both models into odd ratios to find the impact of 
each factor on the probability of a term birth.  
We used linear regression models to estimate the impact of different 
factors on different pregnancy outcome measures. One variable we considered 
in each model was whether a patient was prescribed prenatal aspirin or not. This 
allowed us to analyze the impact aspirin may have in addition to other factors. 
We also analyzed the data to see if there was any correlation between 
time on prenatal aspirin and the pregnancy outcome measures. This was to see 
if there was any modeling we could possibly do regarding the time on prenatal 
aspirin variable. 
Some of the patients had incomplete data, and so we only used patients’ 







Comparison of Pregnancy Outcomes Between the Aspirin-Prescribed 
Group and the Non-Prescribed Group 
We analyzed data from 2648 women. The characteristics of the study 
population of the aspirin prescribed group (380 women) and non-prescribed 
group (2268 women) are presented in Table 2. Characteristics include average 
age, average gestational age, race, and medical history of these two groups.  
The birthweight and Apgar scores at one and five minutes are commonly 
measured for the assessment of the general condition of neonates at birth 
(Simon et al., 2020). To determine whether there are any differences in Apgar 
scores at one and five minutes and birthweights between the aspirin-prescribed 
and the non-prescribed groups, we conducted Welch Two Sample T-tests.  As 
shown in Figures 2 and 3 as well as Table 3, there were differences in the 
sample means, and the prescribed group had a statistically significant lower 
average for all three pregnancy outcome measures. We also analyzed the rates 
of preterm and term birth in these two groups.  As shown in Table 4, the 
prescribed population had a significantly higher rate of preterm births than the 
non-prescribed group. Taken together, our analysis suggests that the prescribed 
group had worse pregnancy outcomes.  This is not entirely unexpected as 
women in the prescribed group were initially prescribed aspirin because they had 





Table 2.  Characteristics of the Study Participants 
 
 
Characteristic Aspirin Group  
N = 380 
Non-aspirin Group  
N = 2268 
   
Gestational age at Intake (days) 65 72 
   
Median age at intake 32 29 
   
Race or Ethnicity - Number (%)   
   
White 77 (20.3) 806 (33.5) 
   
Black 254 (66.8) 934 (41.2) 
   
Hispanic 16 (4.2) 146 (6.4) 
   
Native American 1 (0.3) 5 (0.2) 
   
Middle Eastern 0 (0) 4 (0.2) 
   
Asian 10 (2.6) 102 (4.5) 
   
Pacific Islander 0 (0) 2 (0.1) 
   
Other or Mixed Race 2 (0.5) 14 (0.6) 
   
Declined/Not Available 20 (5.3) 255 (11.2) 
   
Smoke History 73 (19.2) 335 (14.8) 
   
History of Preeclampsia 64 (16.8) 35 (1.5) 
   
History of Multifetal Gestation 30 (7.9) 38 (1.7) 
   
Chronic Hypertension 116 (30.5) 65 (2.9) 
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7.64! 7.90! (90.47,!90.07)! 8.5e903*!
! ! ! ! !
Mean!Apgar!!
at!5!minute!
8.61! 8.77! (90.29,!90.03)! 1.8e902*!











Logarithmic Modeling and Odds Ratios Comparison 
	
Many risk factors can affect the outcomes of pregnancy. To investigate the 
effects of measured major and moderate factors on preterm and term births, we 
employed R to generate a model that could determine the relationship between 
preterm/term birth and the sum of total major risk factors and the sum of total 
moderate risk factors in both groups of women. Our modeling results show that, 
for the prescribed group, the odds ratios for total major risk factors and total 
moderate risk factors were 0.661 and 1.01, respectively, for a term birth. Only the 
odds ratio for total major risk factors was statistically significant. This analysis 
indicates that for each single increase in major risk factor, there is about a 34% 
decreased chance of having a term birth in the prescribed group (Table 5). In 
addition, the y-intercept of the model suggests that if a patient were prescribed 























& ! ! !
Term!Births& 284!(82.1)! 1856!(91.4)! 7.7e628!
& ! ! !
Preterm!Births& 62!(17.9)! 174!(8.6)! 7.7e628!
& ! ! !
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times better odds at a term birth than a prescribed patient who had just even one 
risk factor.  
On the other hand, the odds ratios for total major risk factors and total 
moderate risk factors were 0.445 and 0.852, respectively, for the not prescribed 
group.  Both odds ratios were statistically significant. Thus, for every increase in 
one major risk factor, there is about a 56% decreased chance of having a term 
birth in the not prescribed group and for each single increase in moderate risk 
factor, there is about a 15% decreased chance of having a term birth in this 
group.  Additionally, the y intercept of the model indicates that if a patient were 
not prescribed aspirin and had no major and no moderate risk factors, she would 
have 17.8 times better odds at a term birth than a patient who was not prescribed 
aspirin and had even just one risk factor.  
Together, results from our modeling analysis show that the prescribed and 
non-prescribed groups had different factors that statistically affect the odds of a 
term birth. Consistent with the result from our earlier chi square analysis, our 
modeling studies also show that, as judged from the y-intercepts for these two 
groups, the prescribed group had a lower chance of having a term baby than the 
not prescribed group.  Interestingly, our results indicate that the chance of having 
a term baby in the non-prescribed group is affected by both total major and total 
moderate risks, while the odds of having a term baby for the prescribed group is 
affected only by total major risks. Additionally, an increase in one major risk  
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Table 5. Analysis of the relationship between preterm/term birth and major 































































































































































































































































factor has a larger adverse effect on the odds of a term birth in patients not 
prescribed aspirin compared to patients who are prescribed aspirin (56% vs 34% 
decrease).  Therefore, our results suggest that prenatal aspirin may counter the 
effects of moderate risk factors as well as alleviate the effect of major risk factors 
on pregnant women having a term birth.  
 
 
Investigation of the Relationships between Pregnancy Outcomes and Risk 
Factors and Prenatal Aspirin Intake Using Linear Models 
  
Given the above observed apparent counteracting effect of prenatal 
aspirin on major and moderate risk factors exerted on term birth, we employed 
linear models to further investigate the relationship between pregnancy outcomes 
(Apgar score at 1 minute, Apgar score at 5 minutes, and birthweight) and sum of 
total major risk factors, sum of total moderate risk factors, and prenatal aspirin 
intake (patients were prescribed the PNA). Additionally, we utilized the linear 
models to examine the interaction effect between prenatal aspirin intake, total 
major risk factors, and total moderate risk factors. First, we investigated these 
relationships for Apgar score at one minute with a linear model. We found that 
only total moderate risk factors, being prescribed PNA, and the interaction 
between total moderate risk factors and being prescribed PNA had a statistically 
significant impact on Apgar score at one minute (Table 6). We then created a 
new linear regression model that was a simplified version of the previous model. 
This model only included the variables of significant effect-total moderate risk 
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factors, prescribed/not prescribed aspirin, and the interaction effect between the 
two.  
 
To determine if the simplified model was statistically sound to use, we 
conducted a partial F test. This test concluded that our simplified model was 
sound. Our analysis using this simplified model showed that the coefficients for 
total moderate risk, being prescribed aspirin, and the interaction between the two 
were -0.15843, -0.58185, and 0.14127, respectively (Table 7).  
This result means that the effect of total moderate risk on Apgar score at 
one minute is dependent on whether a patient is prescribed aspirin or not. If a 
pregnant woman is not prescribed aspirin, for every increase in one moderate 
risk, the Apgar score at one minute will decrease by 0.15843. On the other hand, 
Table 6. Relationship between Apgar score at 1 minute and different variables 
 Estimated Coefficient p value 
   
Intercept 8.2518 < 2e-16* 
   
Total Major Risks 0.0310 0.857389 
   
Total Moderate Risks -0.14408 8.34e-06* 
   
Prescribed/Not prescribed -0.58302 7.89e-04* 
   
Moderate x Prescribed 0.13618 2.26e-03* 
   
Major x Prescribed 0.14075 0.316708 
   
Moderate x Major -0.05989 0.220626 
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Table 8. Relationship between Apgar score at 5 minute and different variables 
 Estimated Coefficient p value 
   
Intercept 8.910192 < 2e-16* 
   
Total Major Risks -0.099771 0.857389 
   
Total Moderate Risks -0.055430 8.34e-06* 
   
Prescribed/Not prescribed -0.268580 7.89e-04* 
   
Moderate x Prescribed 0.050346 2.26e-03* 
   
Major x Prescribed 0.088658 0.316708 
   
Moderate x Major -0.001817 0.220626 
   
if a pregnant woman is prescribed aspirin, every increase in one moderate risk 
only decreases the Apgar score at one minute by 0.01716. In other words, being 
prescribed aspirin reduces the total moderate risk factor’s reduction of Apgar 






Table 7. Relationship between Apgar score at 1 minute and selected variables 
 Estimated Coefficient p value 
   
Intercept 8.27166 < 2e-16* 
   
Total Moderate Risks -0.15843 4.43e-07* 
   
Prescribed/Not prescribed -0.58185 1.27e-04* 
   
Moderate x Prescribed 0.14127 1.41e-03* 
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We also carried out similar linear model studies for an Apgar score at five 
minutes based on the same factors as described above. We found that the only 
significant coefficients were total moderate risk and being prescribed PNA (Table 
8). We again generated a simplified linear model. From the partial F test, we 
concluded that our simplified model was statistically sound. Our analysis using 
this model showed that the coefficients for total moderate risks, prescribed, and 
the interaction effect between the two were all statistically significant (Table 9). 
The coefficients for total moderate risk, prescribed, and the interaction effect 
between the two were -0.06096, -0.28494, and 0.05598, respectively (Table 9). 
Similar to what we observed for an Apgar score at one minute, if a patient is 
prescribed aspirin, it decreases the reducing effect of total moderate risks by 
0.05598.  
 
Lastly, we generated a linear model for birthweight using the same 
strategy described above. We found that the only statistically significant variables 
Table 9.  Relationship between Apgar score at 5 minute and selected variables 
 Estimated Coefficient p value 
   
Intercept 8.91318 < 2e-16* 
   
Total Moderate Risks -0.06096 8.39e-04* 
   
Prescribed/Not prescribed -0.28494 1.26e-03* 
   
Moderate x Prescribed 0.05589 3.0e-02* 
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that had an effect on birthweight were total major risk factors, prescribed/not 
prescribed, and the interaction effect between the two (Table 10). Our analysis 
using a simplified model showed that the birthweight was affected by total major 
risks, being prescribed aspirin, and the interaction effect between the two (Table 
11). For each increase in major risk factor, the birthweight decreases by 205.34 
grams and 24.81 for neonates born to women not prescribed PNA and 
prescribed PNA, respectively (Table 11). In other words, being prescribed aspirin 
can increase the birthweight by 180.53 grams for every increase by one in total 
major risk factors. Together, the results shown in Tables 6-11 indicate the 
beneficial effects of prenatal aspirin on pregnancy outcomes as measured by 
Apgar scores at 1 and 5 minutes and birthweight. 
 
Correlation Test for the Relationship Between the Length of PNA Intake and 
Apgar Scores and Birthweight 
 We also examined the relationship between the length of PNA intake and 
Apgar scores at one and five minutes and birthweight. We found that correlation 
between time on PNA (days) and Apgar score at one minute to be 0.07126481, 
the correlation between time on PNA and Apgar score at five minutes to be 
0.1078263, and the correlation between time on PNA and birthweight to be 
0.1638654 (Table 12). Since the results suggested a very weak correlation, we 








Table 11. Relationship between birthweight and selected variables 
 Estimated Coefficient p value 
   
Intercept 3274.10 < 2e-16* 
   
Total Moderate Risks -205.34 7.1e-08* 
   
Prescribed/Not prescribed -163.34 2.26e-04* 
   
Moderate x Prescribed 180.53 5.73e-04* 
   
Table 10.  Relationship between birthweight and different variables 
 Estimated Coefficient p value 
   
Intercept 3324.352 < 2e-16* 
   
Total Major Risks -208.424 1.48e-03* 
   
Total Moderate Risks -22.140  6.94e-02 
   
Prescribed/Not prescribed -246.572  0.000177* 
   
Moderate x Prescribed 32.223 5.61e-02 
   
Major x Prescribed 169.348 1.48e-03* 
   
Moderate x Major 4.955 0.789117 





 Table 12. Correlation between pregnancy outcomes and length of PNA intake 
Test Correlation 
  
Apgar score at 1 minute 0.0713 
  








From this retrospective study, we found that prenatal aspirin appears to 
have a positive effect in birth outcomes. This is shown by the both the logarithmic 
modeling and the multivariable linear modeling methods. In the logarithmic 
modeling, we found that there may be a decrease in the effect of total moderate 
risk in the pregnancy outcome measure of term vs preterm. In the multivariable 
linear modeling, we found that the effect of being prescribed prenatal aspirin may 
negate the effects of total major risk factors on the pregnancy outcome of Apgar 
score at five minutes. In addition, we found that the odds ratio for a term birth 
versus a preterm birth is dependent on different variables depending on whether 
a patient was prescribed aspirin or not. This suggests aspirin has a possible 
counter effect on some risk factors that influence a birth outcome. This is 
supported by our observations on different linearities between different factors 
which influence different birth outcomes.  
In this study, patients were generally prescribed prenatal aspirin when 
they scored high enough with regards to major and moderate risk factors that 
these women were considered to be at greater risk for preeclampsia. This study 
demonstrates that for these women who were considered to be at higher risk for 
preeclampsia, there was an association between aspirin and a decreased impact 
of certain preeclampsia risk factors on select birth outcomes. 
The perceived benefits of prenatal aspirin that we observed in this study 
are in line with previous findings. What is interesting is that we could identify 
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certain benefits of prenatal aspirin intake in this retrospective analysis with a non-
randomized and risk factor un-balanced cohort. The results in this study can be 
added to the accumulating evidence on the benefits of prenatal aspirin in the 
prevention of preeclampsia.  
Still, one of the biggest problems facing the prescription of prenatal aspirin 
is patient adherence. While there are many studies that show the proven 
beneficial effects of prenatal aspirin with little risk of pregnancy complications, 
many women are still hesitant to adhere to their physician’s orders because there 
is common perception among pregnant women that aspirin has more risks than 
benefits (Damase-Michel et al., 2009).  
One possible solution to this is telemedicine. As healthcare organizations 
continue to integrate more technological services into their practices, an 
increasing number of providers are turning to telemedicine. Telemedicine is the 
delivery of healthcare information such as diagnoses, treatments, prevention, 
and evaluation using information and communication technologies (Kruse et al., 
2017). The potential convenience, relative low cost, and increased accessibility 
that telemedicine provides can lead to an increase in confidence and knowledge 
as well as improved health status among patients (Akesson et al., 2007).  
Additionally, a systematic review of text messaging interventions (TMIs) 
found that because TMIs can reach large groups of people at a low cost per 
person, they have the potential to incorporate qualities associated with more 
effective health interventions. TMIs incorporate qualities that lead to more 
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effective communication between provider and patient such as tailoring 
messages, interactivity, personalization, and high message repetition (Hall et al., 
2015). Further studies, such as the study conducted by Park et. al. reviewed the 
effectiveness of text messages on medication adherence and reported 
statistically significant improvements in adherence rates and biomarkers. 
Furthermore, it was found that there was an increased positive effect on 
medication adherence occurring in studies that applied tailored or personalized 
messages. Specifically, it was determined that there was increased adherence 
as well as higher participant satisfaction (Park et al., 2014). Previous studies 
have shown the promise of telemedicine solutions on patient outcomes. In a 
randomized controlled trial, it was found that daily educational text messages 
increased the adherence of an oral contraceptive pill when compared to 
providing routine care alone (Castano et al., 2012). Another study showed similar 
results in antihypertensive drug adherence when using text messaging as an 
educational tool (Varleta et al., 2017). Thus, telemedicine and the use of tailored 
or personalized messages could prove to be a valuable intervention in improving 
adherence of prenatal aspirin. 
 
Study Limitations 
Some limitations to this study include that this was a retrospective study 
as opposed to a double blind randomized study. Additionally, some of the 
patients had missing data, so we had to exclude some patients from the analysis 
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because they did not have complete data. Furthermore, the patient data from this 
study is from 2017 and 2018. Since the time of data collection, the BMC prenatal 
aspirin team has worked diligently to raise awareness of the benefits of prenatal 
aspirin and increase adherence of prenatal aspirin. Thus, the data from the study 
may not accurately represent current attitudes towards prenatal aspirin, and 
more current data likely would be more accurate. 
Additional limitations to this study are that we used logarithmic modeling 
and multivariate linear modeling to analyze the data. With these models, we 
needed to make statistical assumptions about both the population and factors we 
analyzed. For our logarithmic model, we assumed that there is little or no 
correlation between total moderate and total major factors. For our linear models, 
we assumed that the relationship between the outcome result and the predictor 
variables was linear. It may very well be the case that there is not a linear 
relationship between the outcome result and the variables.  
Future studies can be conducted to further determine the effect of 
variables related to preeclampsia in pregnancy outcomes.  There have been 
multiple guidelines established that use various variables in the determination of 
determining risk of preeclampsia in pregnant women. More collaborative and 
uniformly established criteria for risk factors would likely result in more 
consistency. 
In addition, future studies can be conducted to address the issue of 
adherence. For example, focus groups can be conducted to determine patients’ 
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attitudes towards prenatal aspirin to determine whether motivational text 






R Code Used: 
prescribed<-read.table("~/Desktop/Prescribed.csv", header=T, sep=",") 






























































chisq.test(matrix(c(284,1856,62,174), nrow=2, byrow=T), correct=F) 
 












plot6<-ggplot(total, aes(x=TOTAL_MAJ_RISK, fill=PRESCRIBED)) + geom_bar() 
plot6+facet_grid(PRESCRIBED ~ .)+scale_x_continuous(name="Total Major 
Risks")+scale_y_continuous(name="Frequency")+ggtitle("Frequency of Total 
Major Risks") 
plot7<-ggplot(total,aes(x=TOTAL_MOD_RISK, fill=PRESCRIBED)) + geom_bar() 
plot7+facet_grid(PRESCRIBED ~ .)+scale_x_continuous(name="Total Moderate 












plot9+scale_x_continuous(name="Apgar Score at Five Minutes")+ggtitle("Density 




plot10+scale_x_continuous(name="Apgar Score at One Minute")+ggtitle("Density 
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